Form 4 for NBIX NEUROCRINE BIOSCIENCES INC
Accepted 2026-02-03 00:00:00 ET · period of report 2026-01-31 · accession 0001201096-26-000003 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-02-03 | 2026-01-31 | NBIX | GORMAN KEVIN CHARLES | Dir | F - Tax | $136.06 | -2,845 | 516.9K | -0.5% | -$387.1K |
| D | 2026-02-03 | 2026-01-31 | NBIX | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | +5,142 | 519.7K | +1.0% | $0 |
| D | 2026-02-03 | 2026-01-31 | NBIX | GORMAN KEVIN CHARLES | Dir | M - OptEx | $0.00 | -5,142 | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-31 | F | D | 2,845 | $136.06 | 516,893 | D | — | — | (F1) Shares withheld by Neurocrine Biosciences, Inc. (the "Company" or "Issuer") to satisfy tax withholding requirements on vesting of restricted stock units ("RSUs"). No shares were sold. (F2) 516,893 of the outstanding shares are held by the Gorman and Blais Family Trust, of which Dr. Gorman has voting and investment power. |
| 2 | Common | Common Stock | 2026-01-31 | M | A | 5,142 | $0.00 | 519,738 | D | — | — | |
| 3 | Derivative | Restricted Stock Unit | 2026-01-31 | M | D | 5,142 | $0.00 | 0 | D | — · — to — | 5,142 Common Stock | (F3) Each RSU represents a contingent right to receive one share of the Issuer's Common Stock. (F4) This RSU was granted to the Reporting Person on January 31, 2022. In accordance with the terms of the RSU, the award vested as to 5,141 shares on January 31, 2023, vested as to 5,141 shares on January 31, 2024, vested as to 5,141 shares on January 31, 2025, and vested as to 5,142 shares on January 31, 2026, subject to the terms and conditions of the award. |